pubmed.ncbi.nlm.nih.gov

Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine - PubMed

Randomized Controlled Trial

Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine

M J A Láinez et al. Cephalalgia. 2006 Mar.

Abstract

Preference is a composite, patient-oriented endpoint incorporating efficacy, tolerability, formulation, and convenience of medications. The objective of this study was to compare patient preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. In this multicentre, open-label, two-period, crossover study, out-patients were randomly assigned to treat the first of two moderate to severe migraines with rizatriptan or eletriptan and the second with the alternate therapy. Patients completed diary assessments at baseline and up to 24 h after taking study medication. At the last visit, patients completed a psychometrically validated preference questionnaire. A total of 372 patients (mean age 38 years, 85% female) treated two migraine attacks, and 342 patients (92%) expressed a preference for treatment. Significantly more (P < or = 0.001) patients preferred rizatriptan 10-mg wafer [61.1%; 95% confidence interval (CI) 55.7, 66.3] to eletriptan 40-mg tablet (38.9%; 95% CI 33.7, 44.3). The most common reason given for preference of either treatment was speed of headache relief. At 2 h, 80% and 69% of patients reported that rizatriptan and eletriptan, respectively, was convenient or very convenient to take (mean convenience score 1.99 vs. 2.31, respectively; P < or = 0.001). Both triptans were well tolerated. In this head-to-head study designed to evaluate global patient preference, significantly more patients preferred the rizatriptan 10-mg wafer to the eletriptan 40-mg tablet for acute treatment of migraine. The single most important reason for preference was speed of relief, consistent with results from previous preference studies.

PubMed Disclaimer

Cited by

Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of life.
Amoozegar F, Pringsheim T. Amoozegar F, et al. Patient Prefer Adherence. 2009 Nov 3;3:251-8. doi: 10.2147/ppa.s6152. Patient Prefer Adherence. 2009. PMID: 19936168 Free PMC article.
Prophylaxis of migraine: general principles and patient acceptance.
D'Amico D, Tepper SJ. D'Amico D, et al. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1155-67. doi: 10.2147/ndt.s3497. Neuropsychiatr Dis Treat. 2008. PMID: 19337456 Free PMC article.
Eletriptan: a review of its use in the acute treatment of migraine.
McCormack PL, Keating GM. McCormack PL, et al. Drugs. 2006;66(8):1129-49. doi: 10.2165/00003495-200666080-00010. Drugs. 2006. PMID: 16789799 Review.
Are the current IHS guidelines for migraine drug trials being followed?
Hougaard A, Tfelt-Hansen P. Hougaard A, et al. J Headache Pain. 2010 Dec;11(6):457-68. doi: 10.1007/s10194-010-0257-5. Epub 2010 Oct 8. J Headache Pain. 2010. PMID: 20931348 Free PMC article. Review.
Key points in migraine prophylaxis: patient perspective.
D'Amico D, Tepper SJ. D'Amico D, et al. Neurol Sci. 2009 May;30 Suppl 1:S39-42. doi: 10.1007/s10072-009-0056-4. Neurol Sci. 2009. PMID: 19415424 Review.

Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine - PubMed